Diabetes medication articles covering metformin, insulin, GLP-1 medicines, SGLT2 inhibitors, device-related safety, side effects, and practical questions to ask.Medication decisions should be individualized. Do not start, stop, or change prescribed treatment based on online information without clinician guidance.
A Lancet Diabetes & Endocrinology consensus statement highlights nutrition, muscle, function, GI symptoms, and psychological support during incretin therapy.
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or type 2 diabetes, but long-term safety data remain limited.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
